Vector Manufacturing Partner VintaBio offers end-to-end viral vector development and manufacturing across AAV, LVV, adenoviral and Vero-based platforms, serving preclinical through clinical programs with scalable production, high product quality, and reliable timelines.

Capacity Growth The 22,500 square foot Philadelphia facility funded with $64M is designed to streamline cell and gene therapy manufacturing, enabling scalable capacity to support multiple programs and faster scale-up.

Academic and Talent Partners Strategic collaboration with The Wistar Institute and local skills initiatives demonstrates access to research talent and partner-led development, creating business development opportunities with academic and early-stage programs.

Rare Disease Focus VintaBio emphasizes speed and reliability for rare and genetically defined diseases, making it an attractive partner for sponsors needing rigorous process control and predictable clinical supply.

Growth and Leadership Leadership expansion, key appointments in commercial and operations roles, and data-driven validation through VintaProcess showcased at industry forums indicate a mature, scalable go-to-market and manufacturing platform.